|

PD-1 Inhibitors Clinical Trials

7 actively recruiting trials

No change since August 2026

Also known as: Nivolumab, Pembrolizumab

Pipeline

Phase 2: 4

Top Sponsors

  • Ming-Yuan Chen2
  • Sun Yat-sen University1
  • Shandong Cancer Hospital and Institute1
  • Quanli Gao1
  • Peking University People's Hospital1

Indications

  • Cancer7
  • Recurrent or Metastatic Nasopharyngeal Carcinoma2
  • Liver Disease1
  • Efficacy, Team1
  • Adverse Event1

Other7 trials

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Phase 2
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Phase 2
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma
Phase 2
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
Phase 2
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
N/A
The Immune Assessment of PD-1 Antibody Therapy in Tumor

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.